A Phase 1, Open Label, Single Dose 3 Way Crossover Study to Evaluate the Bioavailability of a Solid Dose Formulation of PF 04965842 Relative to a Suspension Formulation Under Fasting Conditions and the Effect of Food on the Bioavailability of the Solid Dosage Formulation of Pf 04965842 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2014
Price : $35 *
At a glance
- Drugs Abrocitinib (Primary)
- Indications Lupus-like syndrome
- Focus Pharmacokinetics
- Sponsors Pfizer
- 15 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 18 Jun 2014 New trial record